Drug Profile


Alternative Names: 659032; GSK 659032; SB-659032

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline; Human Genome Sciences
  • Developer GlaxoSmithKline
  • Class Acetamides; Cardiovascular therapies; Piperidines; Quinolines
  • Mechanism of Action 1-alkyl-2-acetylglycerophosphocholine esterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • Discontinued Atherosclerosis

Most Recent Events

  • 22 Dec 2016 GlaxoSmithKline withdrew a phase I trial in Alzheimer's disease in USA (NCT02130661)
  • 17 Apr 2016 Biomarkers information updated
  • 31 Mar 2015 Rilapladib is in phase II development for Alzheimer's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top